A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced Malignancies
Latest Information Update: 06 Mar 2023
At a glance
- Drugs MK 8353 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms MK-8353-013
- Sponsors Merck Sharp & Dohme
- 09 Dec 2022 Status changed from active, no longer recruiting to completed.
- 20 Oct 2022 Planned End Date changed from 18 Nov 2022 to 2 Dec 2022.
- 20 Oct 2022 Planned primary completion date changed from 18 Nov 2022 to 2 Dec 2022.